Plasmablastic lymphoma occurring in ulcerative colitis during treatment with immunosuppressive therapy.
Hideharu OgiyamaYoko MurayamaShusaku TsutsuiTetsuya IwasakiDaisuke KuriyamaMasashi HorikiKazuho ImanakaHayato KimuraMegumu InoueHiroyasu IishiPublished in: Clinical journal of gastroenterology (2023)
A 53-year-old man who had a history of ulcerative colitis (UC) for 2 years underwent colonoscopy as regular follow-up. The results showed an elevated lesion in the descending colon, which was diagnosed as plasmablastic lymphoma (PBL) based on pathological findings. In situ hybridization for the Epstein-Barr virus-encoded RNA probe was positive. Fluorescence in situ hybridization revealed rearrangement of the MYC gene. He had been taking prednisolone, 5-aminosalicylic acid, azathiopurine, and ustekinumab at the diagnosis of PBL and had multiple prior therapies for UC including infliximab, tacrolimus, and tofacitinib due to steroid dependence. PBL is a rare aggressive B cell lymphoma initially described in the oral cavity of human immunodeficiency virus positive patients and it is suspected to have an association with immunocompromised status of patients. The number of cases of PBL in inflammatory bowel disease (IBD) patients is extremely rare. All these patients were administered immunosuppressive therapy including thiopurines or biologics. IBD patients with immunosuppressive therapy have a higher potential for developing lymphoproliferative disorders. Clinicians should be aware of the risk of lymphoma, including PBL.
Keyphrases
- end stage renal disease
- epstein barr virus
- human immunodeficiency virus
- newly diagnosed
- chronic kidney disease
- ejection fraction
- diffuse large b cell lymphoma
- prognostic factors
- hepatitis c virus
- rheumatoid arthritis
- gene expression
- palliative care
- dna methylation
- antiretroviral therapy
- single cell
- hiv infected
- climate change
- mesenchymal stem cells
- bone marrow
- cell therapy
- hiv positive
- hiv aids
- mechanical ventilation
- energy transfer